Rna Diagnostics is dedicated to improving the management of cancer treatments.
The RNA Disruption Assay™ (RDA™) will provide physicians with an evaluation
of how patients are responding to cancer treatments. In real time.
If the cancer drugs are working, the physician and patient can continue with confidence.
If the cancer drugs are not working well enough, physicians may consider alternate treatments.
For patients, this means avoiding harmful side effects and an opportunity to improve outcomes.
This is personalized medicine.